Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04573478 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04573478 · ClinicalTrials.gov record · last posted 2026-06-04

Atrasentan in Patients With IgA Nephropathy

Study acronym: ALIGN
StatusActive, Not Recruiting
PhasePhase 3
Started2020-12-11
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.

Amendment record 21 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 21 times since 2020-09-28; most recent amendment 2026-06-01. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2023-05-26
Status change Recruiting→Active, Not Recruitingv14
2021-01-11
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT04573478
Lead Sponsor Novartis Pharmaceuticals
Conditions IgA Nephropathy, Immunoglobulin A Nephropathy
Enrollment 404 participants
Start Date 2020-12-11
Primary Completion 2028-04-14 (estimated)
Study Completion 2028-04-14 (estimated)
Updated on ClinicalTrials.gov 2026-06-04